WAVEMAN · COMPANY

DXR · Daxor Corp

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

DXR

Name: DAXOR CORP (DXR) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

DAXOR CORP

FUNDS & TRUSTS · REGISTERED INVESTMENT COMPANY · CIK 0000027367

C-SUITE BUYING · 2☆ WATCH

INSIDER NET · 180D

$19.0K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$19.0K over 180 days

below 55% of Funds & Trusts

CONGRESS

no member of Congress has reported trading it

FUNDS

8 funds added or opened last quarter

below 97% of Funds & Trusts

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

1.0 days to cover · settled 2026-07-31

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +1.2%

+1.2%12M

INSIDER BUY

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders are net buyers of their own stock.

The record shows a net $19.0K bought by insiders over 180 days, 8 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

RCG ECAT BCAT ASA NMFC RWAY MEGI GF PFX TPVG EMO CPZ

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, DAXOR CORP insiders bought a net $19.0K of stock across 21 Form 4 purchases and sales, with 2 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Feldschuh Michael Richard

Chief Executive Officer

BUY

2026-04-08

1,000.0

$9.1K

Michel Robert J

Chief Financial Officer

BUY

2026-03-31

1,000.0

$9.9K

Feldschuh Michael Richard

Chief Executive Officer

BUY

2025-04-04

2,063.0

$16.3K

Michel Robert J

Chief Financial Officer

BUY

2025-03-10

1,000.0

$8.0K

Feldschuh Michael Richard

Chief Executive Officer

BUY

2025-03-10

3,360.0

$25.8K

21 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 16 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

VANGUARD CAPITAL MANAGEMENT LLC

48,831.0 sh

$495.6K

Aristides Capital LLC

41,689.0 sh

$429.2K

RENAISSANCE TECHNOLOGIES LLC

29,421.0 sh

$302.9K

SUSQUEHANNA INTERNATIONAL GROUP, LLP

27,131.0 sh

$275.4K

NANO CAP NEW MILLENNIUM GROWTH FUND L P

12,500.0 sh

$128.7K

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Gabelli Global Mini Mites Fund

$3.9K POSITION · AS OF 2026-03-31

0.0%

VANGUARD TOTAL STOCK MARKET INDEX FUND

$469.3K POSITION · AS OF 2026-03-31

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 3 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release

Not applicable

0 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED